Askina Calgitrol Paste Burns

Phase 3WithdrawnNCT01911858

BBraun Medical SAS

Overview

The purpose of the study is to demonstrate that Askina® Calgitrol® Paste is safe to use on III degree burns by quantifying the concentration of silver in the blood during treatment and thus to show that the amount of silver absorbed will be no greater than those reported in the literature.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Conditions

Third Degree Burns

Interventions

Askina Calgitrol PasteDEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (≥\>18 years age). No upper age limit * III degree thermal burns from 2-30% TBSA as determined by the Rule of Nines * Patients who underwent initial treatment within 24 hours after the injury at the latest * Patients who underwent initial treatment directly at the Burn Centre of FNKV or the initial treatment was in accordance with the standard of care of the Centre * All patients will have been hospitalised * Patients who are capable of giving signing informed consent and have done so. Exclusion Criteria: * Patients with electrical or chemical burns * Patients with already infected wounds * Patients taking systemic antibiotics on admission * Patients pregnant or lactating * Patients who fall into "vulnerable population" group with respect to informed consent or who are not capable of giving informed consent * Patients who used or were treated with silver products for other reasons than treatment of the acute burn in the last 3 months * Patients whose other burn wounds are being treated with silver products. * Patients receiving renal dialysis * Known allergy or sensitivity to any of the ingredients in Askina® Calgitrol® Paste. * Simultaneous participation in another interventional clinical trial

Outcomes

Primary Outcomes

The quantification of the amount of silver found in plasma during the treatment

Time frame: Change from Baseline in Blood at 3 days

The quantification of the amount of silver found in plasma during the treatment

Time frame: Change from Baseline in Blood immediately after the removal of the last investigational dressing (the day before necrotomy, an expected average between 3-10 days after inclusion)

Secondary Outcomes

Wound bed and periwound skin conditions

Data will not be recorded at specific time points due to individual changing patterns. The investigator will make a subjective description of the wound bed covered by necrosis, slough/fibrin, granulation tissue and epithelialisation and by the condition of the peri-wound skin.

Time frame: At each dressing change (an expected average of one day)

Clinical signs of infection

Data will not be recorded at specific time points due to individual changing patterns. The presence and intensity of clinical signs of infection will be assessed at the start of the study and at each dressing change using clinical judgment and a scoring system modified from the one published by Trial and al.

Time frame: At each dressing change (an expected average of one day)

Patient comfort

Data will not be recorded at specific time points due to individual changing patterns. The investigator will complete a Likert scale score (1-4, Poor, Fair, Good, Excellent) for each ease of application and ease of removal of Askina Calgitrol Paste at each dressing change.

Time frame: At each dressing change (an expected average of one day)

Number of dressing changes

Data will not be recorded at specific time points due to individual changing patterns.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.